COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Thursday, February 18, 2021
3:00 PM – 4:00 PM ET
Please note this virtual program is at 3:00PM Eastern, 2:00PM Central, 1:00PM Mountain, and 12:00PM Pacific
Program Features:
Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.
The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.
Program Overview:
The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19.
Presenting Faculty:
Shivakumar Narayanan, MBBS, MD
Assistant Professor
Division of Clinical Care and Research
Director, Institute of Human Virology
University of Maryland, School of Medicine
Baltimore, MD
Learning Objectives
After completing the CME activity, learners should be better able to:
- Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
- Critique the efficacy and safety of therapies recently granted EUAs for patients with COVID-19
Target Audience
This activity is intended for pulmonologists, critical care specialists, infectious disease specialists, hospitalists, and hospital pharmacists to help support them in their effort to optimize care of patients with COVID-19.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits:
1.0 ANCC Contact Hour
Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
